Literature DB >> 28967616

Gene editing in T cell therapy.

Yongping Zhang1, Wei Mu2, Haoyi Wang3.   

Abstract

The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise. Gene editing holds tremendous potential for further improvements of T cell therapy. Here we review the applications of gene editing in various T cell therapies, focusing on antiviral strategies and cancer immunotherapies, and discuss the challenges and future prospects.
Copyright © 2017 Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, and Genetics Society of China. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRISPR-Cas9; Gene editing; T cells

Mesh:

Year:  2017        PMID: 28967616     DOI: 10.1016/j.jgg.2017.09.002

Source DB:  PubMed          Journal:  J Genet Genomics        ISSN: 1673-8527            Impact factor:   4.275


  5 in total

Review 1.  CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

Authors:  Sasan Ghaffari; Nastaran Khalili; Nima Rezaei
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

2.  In vitro transcribed sgRNA causes cell death by inducing interferon release.

Authors:  Wei Mu; Na Tang; Chen Cheng; Wen Sun; Xiaofei Wei; Haoyi Wang
Journal:  Protein Cell       Date:  2019-06       Impact factor: 14.870

3.  Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway.

Authors:  Na Li; Na Tang; Chen Cheng; Tao Hu; Xiaofei Wei; Weidong Han; Haoyi Wang
Journal:  Oncoimmunology       Date:  2020-09-24       Impact factor: 8.110

Review 4.  Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar.

Authors:  Bella Guerrouahen; Muhammad Elnaggar; Anjud Al-Mohannadi; Dhanya Kizhakayil; Chiara Bonini; Reuben Benjamin; Renier Brentjens; Christian J Buchholz; Giulia Casorati; Soldano Ferrone; Frederick L Locke; Francisco Martin; Axel Schambach; Cameron Turtle; Paul Veys; Hans J van der Vliet; Cristina Maccalli
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

5.  Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.

Authors:  Javier Fierro; Jake DiPasquale; Joshua Perez; Brandon Chin; Yathip Chokpapone; An M Tran; Arabella Holden; Chris Factoriza; Nikhi Sivagnanakumar; Rocio Aguilar; Sarah Mazal; Melissa Lopez; Huanyu Dou
Journal:  Sci Rep       Date:  2022-02-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.